Wir haben ausgewählte Abstracts von unseren Partnern für Sie zusammengestellt.
AbbVie AG
- 2245 | Drug Survival of Risankizumab vs Other Biologics After 13 Months of Treatment Among Patients With PsA in the Multicountry Postmarketing Observational VALUE Study
- 1397 | Sustainability of Clinical Response at Week 52 to Upadacitinib Among Patients With Axial SpA: Data From the SELECT-AXIS 1 and SELECT-AXIS 2 Trials
- 424 | Real-World Effectiveness of Upadacitinib in Patients with Moderate/Severe Rheumatoid Arthritis: 6-Month Data from the Observational UPHOLD Study
Amgen Switzerland AG
- 1691 | 16-Week Results from FOREMOST, a Placebo-Controlled Study Involving Oligoarticular Psoriatic Arthritis Treated with Apremilast
- 1041 | Efficacy of Apremilast on Peripheral and Axial Inflammation in Patients with Psoriatic Arthritis Based on Whole-Body Magnetic Resonance Imaging
- 1414 | Effects of Apremilast on Changes in Cardiometabolic Parameters by Diabetes and Obesity Status in Patients with Psoriatic Arthritis
CSL Vifor
- 0683 | Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients with Renal Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
- 0687 | Avacopan for the Treatment of ANCA-associated Vasculitis. Real World Experience in Spain
- 0688 | Efficacy and Safety Experience with Avacopan Beyond 52 Weeks in the Early Access Program (EAP)
Otsuka Pharmaceutical (Switzerland) GmbH
- 0782 | Comparison of Dual-immunosuppressive and a Voclosporin-based, Triple-immunosuppressive Regimen: A Propensity Analysis of ALMS and AURORA 1 Studies
- 0601 | Selective Renal Tissue Disposition of Voclosporin, Cyclosporine, and Tacrolimus
- 2326 | Efficacy and Safety Outcomes in Patients with Baseline Proteinuria ≥2 g/g
Novartis Pharma Schweiz AG
- 0780 | Assessing Differential Effects of DMARDs on Psoriasis Area and Severity Index and Patient Global Assessment in Subgroups of Patients with Active PsA Treated over 52-weeks with Secukinumab in a Non-Interventional Trial (AQUILA) Using a Multistage Clustering Approach
- 0529 | Sex-dependent Differences in Disease Characteristics Do not Influence Effectiveness of Secukinumab Therapy in Patients with Active Axial Spondyloarthritis in a Non-Interventional Trial (AQUILA)
- 0522 | Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: Results from Subgroup Analyses by Baseline Syndesmophytes and C-reactive Protein Status
Pfizer (Schweiz) AG
- 0518 | Tofacitinib Efficacy and Safety in Patients with Ankylosing Spondylitis by Baseline C-Reactive Protein Levels: A Post Hoc Analysis
- 2113 | Impact of Sociodemographic Factors on Efficacy and Safety of Tofacitinib in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of Phase 2/3/3b/4 Studies
- 1217 | Sex Differences in Perceptions of Psoriatic Arthritis Disease Impact, Management, and Physician Interactions: Results from a Global Patient Survey
sanofi-aventis (schweiz) ag
- 0718 | Clinical and Economic Burden of Polymyalgia Rheumatica in Patients with an Inadequate Response to Glucocorticoids in a Real-World Setting
- 1566 | Exposure-Response Analysis of Sarilumab in Patients with Polymyalgia Rheumatica
UCB Pharma AG
- 2148 | Do High RF Titers Impact Response to TNF Inhibitors? Comparison of Certolizumab Pegol and Adalimumab in Patients with RA and High Titers of RF: A Post Hoc Analysis of a Phase 4 Trial
- 0524 | Efficacy of Certolizumab Pegol in Preventing Anterior Uveitis Flares Compared with Standard Non-Biologic Treatment: A Matched Control Study in High-Risk Patients with Axial Spondyloarthritis
- 1872 | Performance Analysis of a Deep Learning Algorithm to Detect Positive SIJ MRI According to the ASAS Definition in axSpA Patients